PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / WORK PRODUCT DOCTRINE
Discount Rate / WACC Analysis
PBI Platform Contribution Transaction
Prepared by: Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, Massachusetts 02109
December 15, 2022
Author: Dr. Helena Vasquez, Ph.D., Managing Director
Contributing Analyst: Dr. Rohan Chakrabarti, Ph.D., Senior Director
Prepared at Direction of Counsel: Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, Pennsylvania 19103
Attention: Leonard Cross, Partner, and Garrett Simmons, Associate
Kovel Engagement Reference: C&H Matter Number 1018-00009-KV; Kovel Letter dated June 20, 2022
Subject: Analysis of the appropriate weighted average cost of capital ("WACC") for use in the income-method valuation of the platform contribution transaction ("PCT") between Penterra Pharmaceuticals Corp. ("PPC") and Penterra Biopharma International DAC ("PBI"), effective July 1, 2012, in connection with the IRS examination of PPC's transfer pricing for tax years 2017–2020 (Exam Team ID: LB&I-NE-TP-2022-00641).
This memorandum is prepared under the protection of the attorney-client privilege, the tax practitioner privilege under IRC § 7525, and the work product doctrine. It reflects confidential communications made at the direction of counsel in anticipation of litigation or administrative proceedings. This document is not to be disclosed, distributed, or reproduced without the prior written consent of Calderwood & Harkness LLP.
Right-click to update Table of Contents
I. Executive Summary
Whitmore Valuation Group LLC ("Whitmore" or "WVG") has been retained under a Kovel arrangement at the direction of Calderwood & Harkness LLP ("C&H"), counsel to Penterra Pharmaceuticals Corp. ("PPC"), to provide an independent economic analysis of the appropriate weighted average cost of capital ("WACC") for use in the income-method (Discounted cash flow, or "DCF") valuation of the platform contribution transaction ("PCT") between PPC and Penterra Biopharma International DAC ("PBI"). The PCT, effective July 1, 2012, involved the contribution of pre-existing pharmaceutical intangible property by PPC to PBI under a qualified cost-sharing arrangement ("CSA"), in exchange for a lump-sum PCT payment of $312 million.
The purpose of this memorandum is to support the use of a 9.8% WACC in the income-method DCF valuation of the PCT, and to demonstrate that PPC's original $312 million PCT payment falls within the arm's-length range of $278 million to $361 million. The $312 million payment falls centrally within this range and is fully consistent with arm's-length pricing under Internal Revenue Code ("IRC") § 482 and Treasury Regulation ("Treas. Reg.") § 1.482-7.
The Internal Revenue Service ("IRS"), through its economist Dr. Alan Washburne, has applied a WACC of 7.2% in its income-method valuation of the PCT, arriving at a PCT value of approximately $852 million. The IRS contends that PPC's $312 million payment undervalued the pre-existing intangible property by approximately $540 million and has used this purported undervaluation to recharacterize the ongoing CSA cost-sharing ratios and royalty rates for the examination years 2017–2020. The IRS's proposed adjustments total $380.4 million across the four examination years, comprising $235.01 million in CSA cost-sharing adjustments and $188.04 million in royalty adjustments, net of correlative offsets.
It is the central conclusion of this analysis that the IRS's application of a 7.2% WACC is unsupported by market data, ignores pharmaceutical-industry-specific risk factors, understates the appropriate discount rate, and thereby overstates the PCT value by a substantial margin. The 2.6 percentage point difference between PPC's 9.8% WACC and the IRS's 7.2% WACC is the primary driver of the approximately $540 million gap between PPC's PCT valuation and the IRS's proposed PCT value. Because the income-method DCF valuation is highly sensitive to the discount rate — particularly over the extended cash flow projection period applicable to pharmaceutical intangible property — even modest differences in the WACC produce outsized differences in the resulting present value.
While the PCT was executed on July 1, 2012, and the 2012 tax year is outside the scope of the IRS's current examination (which covers tax years 2017–2020), the IRS has used its PCT revaluation as the predicate for recharacterizing the ongoing CSA cost-sharing ratios and royalty rates applicable to the examination years. Accordingly, the WACC determination is critical to the IRS's entire theory of adjustment, and correction of the discount rate alone substantially undermines the basis for the IRS's $380.4 million in total proposed adjustments.
This memorandum should be read in conjunction with the companion PCT Valuation Analysis (Income Method / DCF Approach) report, also prepared by Whitmore Valuation Group LLC and dated December 15, 2022, which presents the full DCF model, revenue projections, and arm's-length range determination.
II. Scope and Methodology
A. Engagement Scope
Whitmore Valuation Group LLC was retained under a Kovel arrangement at the direction of Calderwood & Harkness LLP, counsel to PPC, pursuant to the Kovel Letter dated June 20, 2022 (C&H Matter Number 1018-00009-KV). Under this arrangement, Whitmore provides independent economic analysis and expert advisory services in defense of PPC before the IRS in connection with the Service's examination of PPC's transfer pricing for tax years 2017–2020. All work product, communications, and analyses prepared by Whitmore in this engagement are protected by the attorney-client privilege, the tax practitioner privilege under IRC § 7525, and the work product doctrine.
The specific scope of this memorandum is to determine the appropriate WACC for discounting projected cash flows attributable to the intangible property contributed by PPC to PBI under the CSA. The WACC serves as the discount rate in the income-method DCF valuation of the PCT, which is the subject of the companion PCT Valuation Analysis report. The WACC analysis is integral to determining whether PPC's $312 million PCT payment falls within an arm's-length range, and to evaluating the reasonableness of the IRS's proposed 7.2% WACC and the resulting $852 million PCT valuation.
The PCT involved PBI's acquisition of the rights to develop, manufacture, and commercially exploit PPC's pharmaceutical IP portfolio in territories outside the Americas (specifically, all territories other than North America, Central America, South America, and the Caribbean, collectively the "Non-Americas Territory"). The IP portfolio contributed under the PCT comprised both approved and clinical-stage pharmaceutical compounds, primarily in the therapeutic areas of oncology, immunology, and rare-disease therapeutics. In exchange for these rights, PBI paid PPC a lump-sum PCT payment of $312 million on July 1, 2012.
B. Applicable Regulatory Framework
The analysis in this memorandum is governed by and conducted in accordance with the following regulatory and legal authorities:
IRC § 482 and the Arm's-Length Standard. Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury to distribute, apportion, or allocate gross income, deductions, credits, and allowances between commonly controlled entities if necessary to prevent evasion of taxes or to clearly reflect income. The arm's-length standard, codified in the regulations promulgated under § 482, requires that controlled transactions be priced consistently with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
Treas. Reg. § 1.482-7: Cost-Sharing Arrangements. These regulations govern qualified cost-sharing arrangements, including the valuation of platform contribution transactions. Section 1.482-7(g)(4) prescribes the income method for valuing PCTs, which requires the determination of the present value of the anticipated future income or cost savings attributable to the contributed intangible property, discounted at an appropriate rate.
Treas. Reg. § 1.482-7(g)(4)(vi): Discount Rate for Income Method. This regulation specifically addresses the selection of the discount rate for income-method PCT valuations and requires that the discount rate "reflect the riskiness of the relevant activities and the projected cash flows." This provision is central to the present dispute, as it mandates a risk-adjusted discount rate tailored to the specific characteristics of the IP being valued and the activities being conducted, rather than a generic enterprise-level rate.
Treas. Reg. § 1.482-4: Methods for Determining Arm's-Length Consideration for Intangible Property. These regulations provide the broader framework for transfer pricing of intangible property, including the comparable uncontrolled transaction ("CUT") method and other methods, which inform the reasonableness of the discount rate through implied rates from comparable license agreements.
Treas. Reg. § 1.482-1(d): Best Method Rule. The best method rule requires the use of the method that provides the most reliable measure of an arm's-length result. In the context of discount rate selection, this principle supports the use of the most reliable and well-supported inputs and methodology for constructing the WACC.
OECD Transfer Pricing Guidelines (2017 and 2022 Revisions), Chapters VI and VIII. While not binding on U.S. taxpayers or the IRS, the OECD Guidelines are widely recognized as persuasive authority in U.S. transfer pricing matters, including by the Tax Court. Chapter VI (Special Considerations for Intangibles) and Chapter VIII (Cost Contribution Arrangements) address the valuation of intangible contributions and the appropriate discount rates for income-based valuation methods. These guidelines support the use of risk-adjusted discount rates that reflect the specific characteristics of the intangible assets and the functions and risks borne by the parties to the transaction.
C. Analytical Framework
The WACC is constructed using a standard finance methodology that combines the cost of equity and the after-tax cost of debt, weighted by the market-value proportions of equity and debt in the capital structure. The cost of equity is derived using the Capital Asset Pricing Model ("CAPM"), augmented by a size premium and a company-specific/asset-specific risk premium, consistent with widely accepted valuation practice and the requirements of Treas. Reg. § 1.482-7(g)(4)(vi).
The components analyzed in this memorandum are as follows:
1. Risk-free rate — based on the yield on 20-year U.S. Treasury bonds as of the valuation date;
2. Equity risk premium ("ERP") — the expected excess return on equity markets over the risk-free rate;
3. Industry beta — the systematic risk measure for specialty pharmaceutical companies, derived from a set of publicly traded comparable companies;
4. Size premium — an incremental return adjustment reflecting the empirical observation that smaller companies (and carved-out income streams) command higher risk premiums;
5. Company-specific / asset-specific risk premium — an adjustment for risks unique to the PCT intangible property, including clinical-stage IP risk, geographic and regulatory risk in the Non-Americas Territory, and PBI's nascent operational status;
6. Cost of debt — PPC's after-tax borrowing cost as of the valuation date; and
7. Capital structure weights — the market-value proportions of equity and debt.
The valuation date for all inputs is July 1, 2012, which is the effective date of the CSA and the date on which the PCT payment was made. All inputs are calibrated to market conditions as of the valuation date, consistent with the requirement that the arm's-length analysis be conducted based on the information and circumstances that were available and known at the time of the transaction. Hindsight-based adjustments are expressly excluded from this analysis except where noted for illustrative purposes.
III. Background: PPC and PBI Structure
A. PPC Overview
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol PPCA, and headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on the development, manufacture, and commercialization of innovative therapies in the areas of oncology, immunology, and rare-disease therapeutics.
As of fiscal year 2020, PPC reported annual revenues of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals across its global operations. PPC's market capitalization as of December 31, 2020 was approximately $28.4 billion.
PPC's key commercial products include:
• Veritaxol (oncology): A first-in-class targeted kinase inhibitor approved for the treatment of non-small cell lung cancer and advanced renal cell carcinoma. Veritaxol generated global net sales of approximately $3.12 billion in fiscal year 2020, representing approximately 45.7% of PPC's total revenue.
• Imvara (immunology): A biologic therapy approved for moderate-to-severe autoimmune conditions. Imvara generated global net sales of approximately $1.87 billion in fiscal year 2020.
• Cerulon (rare disease): An enzyme replacement therapy for a lysosomal storage disorder. Cerulon generated global net sales of approximately $620 million in fiscal year 2020.
PPC maintained an active R&D pipeline as of the valuation date (July 1, 2012), with multiple clinical-stage compounds in oncology, immunology, and rare diseases. The company's R&D expenditures averaged approximately 18–20% of revenues during the 2010–2012 period. Several of the clinical-stage compounds in the pipeline as of the valuation date were included in the IP contributed under the PCT.
B. PBI Overview
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under the laws of Ireland, registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, approximately three-and-a-half months before the effective date of the CSA and PCT. PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg société à responsabilité limitée, which is itself 100% owned by PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes, such that PBI is treated as a controlled foreign corporation ("CFC") wholly owned by PPC for U.S. tax purposes.
PBI serves as the IP-holding company and principal entity for the commercialization of PPC's pharmaceutical products in the Non-Americas Territory. PBI holds the rights to develop and exploit the pharmaceutical IP acquired under the PCT and bears the costs and risks of commercialization, including regulatory, marketing, and distribution functions, in its designated territory.
As of fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI employed 185 individuals as of fiscal year-end 2020, an increase from the 52 employees on staff at the time of PBI's establishment and the execution of the CSA in July 2012.
It is relevant to the WACC analysis that PBI maintained substantive operations during the examination years and the period since its establishment, including:
• Approximately 18,000 square feet of office space in Dublin;
• 42 board meetings held during the 2017–2020 examination years;
• €47.2 million in cumulative regulatory expenditures across the Non-Americas Territory; and
• Independent pricing across 68 country markets in the Non-Americas Territory.
However, at the time of the PCT (July 1, 2012), PBI was a newly incorporated entity with only 52 employees, no operating history, and no independent track record of commercializing pharmaceutical products. These facts are relevant to the assessment of company-specific and asset-specific risk premiums, as discussed in Section IV.E below.
C. The Cost-Sharing Arrangement and PCT
The CSA between PPC and PBI became effective on July 1, 2012. Under the CSA, PBI agreed to co-fund qualified R&D costs incurred by the CSA participants in exchange for the rights to develop and exploit certain pharmaceutical IP in the Non-Americas Territory. PPC retained all rights to develop and exploit the IP in the Americas.
In connection with the establishment of the CSA, PBI made a PCT payment of $312 million to PPC on July 1, 2012. This payment represented PBI's buy-in to the pre-existing intangible property that PPC had developed prior to the effective date of the CSA. The pre-existing IP contributed under the PCT consisted primarily of clinical-stage and approved pharmaceutical compounds in the therapeutic areas of oncology, immunology, and rare diseases, together with associated know-how, regulatory filings, and commercialization-related intangibles.
PBI's cost-sharing percentages under the CSA for the examination years 2017–2020, and the corresponding total qualified R&D costs shared under the CSA, were as follows:
The cost-sharing percentages reflect PBI's reasonably anticipated share of the benefits from the intangible development activities, which increased over the examination period as PBI's Non-Americas revenue grew relative to PPC's Americas revenue. The IRS has challenged these cost-sharing percentages, as well as certain intercompany royalty rates, based on its revaluation of the PCT, as described below.
D. IRS Position on PCT Valuation
The IRS Large Business and International Division ("LB&I"), through its Exam Team (ID: LB&I-NE-TP-2022-00641), has challenged PPC's transfer pricing for the examination years 2017–2020. The IRS's primary economic expert, Dr. Alan Washburne, valued the PCT using an income method (DCF approach) with a 7.2% WACC, arriving at a PCT value of approximately $852 million.
The IRS asserts that PPC's $312 million PCT payment undervalued the pre-existing intangible property by approximately $540 million (the difference between $852 million and $312 million). The IRS has used this purported undervaluation as the basis for two categories of proposed adjustments:
1. CSA cost-sharing adjustments: The IRS contends that PBI's cost-sharing percentages for 2017–2020 should be increased to reflect the allegedly higher value of the pre-existing IP contributed by PPC, resulting in proposed adjustments of $235.01 million across the four examination years.
2. Royalty adjustments: The IRS further contends that certain intercompany royalty rates paid by PBI to PPC are understated in light of the higher PCT valuation, resulting in proposed adjustments of $188.04 million across the four examination years.
After correlative offsets, the IRS's total proposed adjustments for the 2017–2020 examination years are approximately $380.4 million. These adjustments flow directly from and depend entirely upon the IRS's PCT revaluation, and the discount rate is the single most significant point of disagreement between the parties' respective PCT valuations.
IV. WACC Component Analysis
A. Risk-Free Rate
1. Selection of Benchmark
The risk-free rate is the foundational component of the CAPM-based cost of equity and represents the theoretical rate of return on an investment with zero default risk and zero reinvestment risk. In practice, U.S. Treasury securities are used as the proxy for the risk-free rate because they carry the full faith and credit of the United States government and are the most liquid, default-risk-free securities available.
For purposes of this analysis, we have selected the yield on the 20-year U.S. Treasury bond as of July 1, 2012 as the risk-free rate proxy. The selection of the 20-year maturity is based on the principle of maturity matching: the duration of the risk-free instrument should approximate the duration of the cash flows being discounted. The pharmaceutical IP contributed under the PCT has an expected useful economic life of approximately 17–22 years, reflecting the remaining patent protection periods, regulatory exclusivity horizons (including orphan drug exclusivity, pediatric exclusivity, and data exclusivity periods in the Non-Americas Territory), and expected duration of commercial cash flows for the contributed compounds. A 20-year Treasury maturity closely matches this expected cash flow duration.
As of July 1, 2012, the yield on the 20-year U.S. Treasury bond was approximately 2.71%. This rate was influenced by the prevailing macroeconomic conditions, including the ongoing recovery from the 2008–2009 global financial crisis, the Federal Reserve's quantitative easing policies, and the European sovereign debt crisis. These factors had compressed Treasury yields to historically low levels. While yields were low in absolute terms, the 20-year maturity appropriately reflects the long-duration nature of the pharmaceutical IP cash flows.
We note that the 20-year Treasury yield as of the valuation date falls within the range of approximately 2.6%–2.8% that prevailed during the June–July 2012 period, as confirmed by Federal Reserve H.15 statistical releases and Vireo Software data.
2. IRS's Risk-Free Rate
Based on our review of Dr. Washburne's analysis, it appears that the IRS selected a shorter-maturity Treasury instrument — specifically, the 10-year U.S. Treasury note yield — as its risk-free rate proxy. The 10-year Treasury yield as of July 1, 2012 was approximately 1.65%, significantly below the 20-year yield of 2.71%.
This selection introduces a maturity mismatch between the risk-free rate and the duration of the projected cash flows. The cash flows attributable to the PCT intangible property extend over a period of approximately 17–22 years, and using a 10-year risk-free rate to discount 20-year cash flows understates the appropriate risk-free rate by approximately 106 basis points. This understatement flows directly through the CAPM calculation and reduces the overall cost of equity and WACC.
The use of a shorter-maturity risk-free rate is inconsistent with established valuation practice, which calls for the risk-free rate maturity to match the duration of the expected cash flows. The mismatch between the IRS's selected risk-free rate and the cash flow duration is a source of downward bias in the IRS's WACC and contributes to the inflated PCT valuation.
For purposes of this analysis, we adopt a risk-free rate of 2.71%, based on the 20-year U.S. Treasury bond yield as of July 1, 2012.
B. Equity Risk Premium ("ERP")
1. Historical ERP
The equity risk premium represents the incremental return that investors demand for holding a diversified portfolio of equity securities rather than risk-free government bonds. The ERP is one of the most significant and debated inputs in the CAPM, and its estimation has been the subject of extensive academic and practitioner research.
The long-term historical arithmetic mean equity risk premium, measured as the excess return of large-company stocks over long-term government bonds, is one widely used approach to estimating the ERP. Based on data from the Westmark Consulting Group (now Sundial Advisors) Cost of Capital Navigator (2012 edition) and the Westmark Solutions Stocks, Bonds, Bills, and Inflation (SBBI) Yearbook (2012 edition), the historical arithmetic mean ERP for the period 1926 through 2011 was in the range of approximately 5.8% to 6.7%, depending on the specific data series and the definition of the risk-free rate benchmark (income return versus yield on long-term government bonds).
The arithmetic mean is the appropriate measure for use in a forward-looking DCF analysis because it represents the expected single-period return and is consistent with the mechanics of discounting a series of uncertain future cash flows. The geometric mean, which is lower, is appropriate for measuring historical realized compound returns but understates the expected future return for discounting purposes.
2. Forward-Looking / Supply-Side ERP
As an alternative to the purely historical approach, some practitioners and academics have advocated the use of a forward-looking or "supply-side" ERP, which is based on the fundamental factors that drive equity returns (earnings growth, dividend yields, and changes in price-to-earnings ratios) rather than historical realized excess returns. The supply-side ERP tends to be somewhat lower than the historical arithmetic mean, typically in the range of 5.0%–6.5% for the period ending in 2012.
However, the appropriate selection of the ERP must also account for the macroeconomic conditions prevailing at the valuation date. As of July 1, 2012, the global financial markets were still recovering from the 2008–2009 financial crisis. The European sovereign debt crisis was ongoing, with heightened uncertainty about the stability of the Eurozone, sovereign default risks in Greece, Portugal, and Spain, and the potential contagion effects on global pharmaceutical markets. The VIX index, a measure of implied equity market volatility, averaged approximately 20–22 during the first half of 2012, elevated relative to pre-crisis norms. These conditions supported a higher, not lower, equity risk premium as of the valuation date.
Additionally, for a pharmaceutical company with significant Non-Americas operations, the ERP must account for the heightened risk perception in international markets, particularly in EMEA — the largest component of PBI's Non-Americas Territory. The European sovereign debt crisis directly affected pharmaceutical pricing and reimbursement regimes in several major European markets, including austerity-driven price cuts in Southern European countries.
After considering both the historical and supply-side approaches, and giving appropriate weight to the elevated risk environment as of the valuation date, we have selected an ERP of 6.10% for purposes of this analysis. This rate falls within the interquartile range of published ERP estimates as of mid-2012 and is consistent with the median of academic and practitioner estimates compiled by Westmark Consulting Group for the 2012 valuation year.
3. IRS's ERP Selection
Based on our reconstruction of Dr. Washburne's analysis, it appears that the IRS selected an ERP of approximately 5.50%, which is at or below the lower bound of the range of well-supported ERP estimates as of the valuation date. While 5.50% is not outside the range of published estimates, it is below the median and below the level supported by the prevailing market conditions. The selection of a below-median ERP mechanically reduces the CAPM-derived cost of equity and, consequently, the WACC. This reduction, in turn, increases the present value of the projected cash flows and inflates the PCT valuation.
We note that even a modest difference in the ERP — such as the 60 basis points between 6.10% and 5.50% — has a meaningful impact on the cost of equity when multiplied by a beta above 1.0, as is the case for specialty pharmaceutical companies. As detailed in Section V below, the ERP difference accounts for approximately 0.6–0.7 percentage points of the overall WACC gap between PPC's 9.8% and the IRS's 7.2%.
C. Beta Analysis — Pharmaceutical Industry Comparables
1. Comparable Company Selection Criteria
The beta coefficient measures the systematic risk of a security relative to the overall equity market. In the CAPM framework, beta captures the portion of a company's total risk that cannot be diversified away and that investors therefore require compensation for bearing. For purposes of this analysis, we derived a pharmaceutical-industry beta from a set of publicly traded comparable companies, rather than relying solely on PPC's own beta, to reduce estimation error and to capture the systematic risk characteristics of the specialty pharmaceutical sector more broadly.
The comparable company selection criteria were designed to identify publicly traded companies with business and risk characteristics similar to PPC and, more specifically, to the Non-Americas pharmaceutical IP portfolio being valued under the PCT. The criteria included:
• Revenue composition: Revenue derived primarily from branded pharmaceutical products in the therapeutic areas of oncology, immunology, and/or rare diseases, consistent with PPC's product portfolio;
• International operations: Significant non-U.S. revenue, defined as non-U.S. revenue constituting at least 30% of total revenue, to capture the geographic risk characteristics relevant to the Non-Americas IP stream;
• Scale: Market capitalization and revenue within a reasonable range of PPC's size as of the valuation date, to minimize distortions from size-related risk differences;
• R&D intensity: Active R&D pipeline with both clinical-stage and approved compounds, reflecting the mixed IP portfolio contributed under the PCT;
• Valuation-date data: Beta and financial data available as of or near the July 1, 2012 valuation date.
2. Beta Comparable Set
Based on these criteria, we identified a set of twelve (12) comparable specialty pharmaceutical and biotechnology companies with sufficient trading history and data availability as of the valuation date. The comparable companies, their key financial characteristics, and their beta estimates are presented in detail in Appendix A to this memorandum. A summary is provided below:
Notes: Raw betas based on 5-year weekly returns versus the S&P 500 Index. Adjusted betas computed using the Westmark Services Inc./Blume adjustment (2/3 × raw beta + 1/3 × 1.0). Unlevered betas computed using the Hamada equation: βu = βL / [1 + (1 - T) × D/E], where T = 35% (2012 corporate tax rate). Market cap and revenue data as of June 30, 2012 (nearest available to valuation date). Data sourced from Crowne Albany Systems and Glenrock Software.
The median unlevered beta for the comparable set is 1.07, and the mean unlevered beta is 1.07. The unlevered betas for the comparable set range from 0.97 to 1.16, with the interquartile range spanning approximately 1.02 to 1.14.
3. Selected Beta
To derive the appropriate re-levered beta for PPC, we re-levered the median unlevered beta using PPC's actual capital structure as of the valuation date. PPC's debt-to-equity ratio as of July 1, 2012 was approximately 0.19 (based on total debt of approximately $2.1 billion and equity market capitalization of approximately $11.1 billion). Using the Hamada equation with a 35% tax rate:
βL = βu × [1 + (1 - T) × D/E] = 1.07 × [1 + (1 - 0.35) × 0.19] = 1.07 × 1.124 = 1.20
We have adopted a re-levered beta of 1.20 for purposes of this analysis. This value is within the interquartile range of the re-levered betas for the comparable companies and is consistent with the systematic risk profile of a specialty pharmaceutical company with significant oncology, immunology, and rare-disease operations and material international revenue exposure.
A beta of 1.20 reflects above-average systematic risk relative to the broad equity market. This elevated beta is appropriate for a specialty pharmaceutical company because pharmaceutical stock returns are significantly influenced by sector-wide factors — including clinical trial outcomes, regulatory decisions, healthcare policy changes, and patent expiration dynamics — that are correlated with broad market movements but amplified relative to the overall market.
We contrast this with the IRS's apparent beta selection. Based on our reconstruction of Dr. Washburne's analysis, the IRS appears to have used a beta of approximately 0.90–0.95, which is below the median of the pharmaceutical comparable set and more consistent with a diversified healthcare or consumer-staples company than a specialty pharmaceutical firm. The IRS's lower beta is a significant driver of the gap between the two WACC estimates, as discussed further in Section V.
4. Pharmaceutical-Industry-Specific Risk Factors Captured by Beta
The beta coefficient for specialty pharmaceutical companies captures several industry-specific sources of systematic risk that are directly relevant to the PCT intangible property:
Clinical development risk. Specialty pharmaceutical companies bear significant exposure to the outcomes of clinical trials, particularly Phase III pivotal trials in oncology. Historical data indicate that the probability of success for oncology compounds progressing from Phase III to approval ranges from approximately 30% to 50%, meaning that a substantial proportion of clinical-stage compounds fail. Several of the compounds included in the PCT IP were in clinical stages of development as of the valuation date, exposing the projected cash flows to meaningful clinical attrition risk.
Regulatory approval uncertainty. The Non-Americas Territory encompasses 68 country markets, each with its own regulatory agency, approval requirements, and timelines. Regulatory uncertainty is amplified in multi-jurisdiction contexts, where a compound approved in one market may face delays, additional clinical requirements, or outright rejection in others. As of the valuation date, PBI faced the prospect of navigating regulatory pathways in markets ranging from the European Medicines Agency ("EMA") to individual national agencies in emerging markets with less transparent and predictable regulatory processes.
Patent cliff risk and generic competition. Pharmaceutical companies face the risk of revenue erosion as patents expire and generic competitors enter the market. For the contributed IP portfolio, several compounds had finite patent protection horizons, and the projected cash flows beyond patent expiration were subject to significant uncertainty regarding the timing and magnitude of generic erosion. This risk is systematic in nature because patent cliffs affect the entire sector and are a primary driver of pharmaceutical stock price volatility.
Pricing and reimbursement uncertainty. In the Non-Americas Territory, pharmaceutical pricing and reimbursement are heavily regulated and subject to government intervention, particularly in European, Asian, and Latin American markets. As of the valuation date, several European countries were implementing austerity-driven pharmaceutical price cuts, and emerging markets presented ongoing uncertainty regarding pricing and market-access policies. These pricing and reimbursement risks affect the entire sector and are captured in the beta estimates of internationally focused pharmaceutical companies.
Currency risk. PBI's revenue and cost streams are denominated in multiple currencies, including the euro (EUR), British pound (GBP), Japanese yen (JPY), and various emerging-market currencies. Currency fluctuations directly affect the U.S.-dollar-equivalent value of the Non-Americas cash flows and introduce systematic risk that is partially captured by the betas of internationally diversified pharmaceutical companies.
D. Size Premium
1. Rationale for Size Premium
Empirical research has consistently demonstrated that smaller companies earn higher returns than predicted by the CAPM alone, after controlling for beta. This phenomenon, known as the size effect, is captured by adding a size premium to the CAPM-derived cost of equity. The size premium reflects the fact that smaller companies and smaller income streams are subject to risks — including lower liquidity, greater concentration, less diversification, and higher information asymmetry — that are not fully captured by beta.
While PPC is a publicly traded large-cap company with a market capitalization of approximately $11.1 billion as of the valuation date, the cash flows being valued in the PCT represent a carve-out of PPC's operations — specifically, the Non-Americas IP exploitation income stream. The relevant unit of analysis for discount rate purposes is not PPC as a whole, but rather the specific income stream attributable to the contributed IP in the Non-Americas Territory. This carved-out income stream has characteristics more analogous to a mid-cap specialty pharmaceutical company: it represents a subset of PPC's product portfolio, is limited to specific geographic markets, and — at the valuation date — was to be executed through a newly incorporated entity (PBI) with only 52 employees.
Moreover, PBI itself was a newly created entity with no operating history, no established customer relationships in the Non-Americas markets, and no proven track record of independent commercialization. The risks associated with this nascent operation are more consistent with a smaller, less diversified entity than with a mature large-cap pharmaceutical company.
2. Size Premium Quantification
Based on data from the Westmark Consulting Group Risk Premium Report (2012 edition) and the SBBI Valuation Edition, the size premium applicable to companies in the mid-cap range (defined by market capitalization of approximately $2 billion to $10 billion, which approximates the scale of the Non-Americas carve-out) was in the range of approximately 0.80% to 1.40% as of the valuation date, depending on the specific size metric used (market capitalization, total assets, revenue, or number of employees).
For purposes of this analysis, we have selected a size premium of 1.07%, based on the mid-point of the applicable decile range from the Westmark Consulting Group data, adjusted for the specific characteristics of the carved-out Non-Americas income stream. This size premium is applied in addition to the CAPM-derived cost of equity (i.e., risk-free rate + beta × ERP) to arrive at the total cost of equity.
We note that the IRS's analysis appears to have either omitted the size premium entirely or applied a significantly smaller size premium. The omission or understatement of the size premium contributes directly to the understated 7.2% WACC. The failure to include a size premium is particularly problematic in this context because the cash flows being valued are those of a carved-out income stream to be exploited by a newly formed entity, not the cash flows of a mature, diversified large-cap enterprise.
E. Company-Specific / Asset-Specific Risk Premium
1. Justification. The CAPM, even when augmented by a size premium, may not fully capture all of the risks associated with a specific investment or income stream. In such cases, valuation practice and the regulatory framework under Treas. Reg. § 1.482-7(g)(4)(vi) support the addition of a company-specific or asset-specific risk premium (sometimes referred to as an "alpha" or "unsystematic risk premium") to reflect risks that are unique to the particular investment and are not captured by the market-based components of the CAPM.
The PCT involves the contribution of intangible property at various stages of development — including both approved compounds and clinical-stage compounds — with inherently higher risk than PPC's overall operations. The cash flows to be discounted represent the future income from exploiting this specific IP portfolio in the Non-Americas Territory, a geographic region that adds multiple layers of risk not fully reflected in the beta, ERP, or size premium:
• Geographic, regulatory, and market-access risk: The Non-Americas Territory encompasses 68 country markets across Europe, the Middle East, Africa, Asia-Pacific, and other regions. Each market has its own regulatory approval pathway, pricing and reimbursement regime, competitive landscape, and market-access infrastructure. The heterogeneity and complexity of operating across 68 regulatory jurisdictions introduce risks that are specific to this particular income stream.
• Concentration risk: At the valuation date, the Non-Americas revenue projections were heavily dependent on Veritaxol, PPC's oncology blockbuster, which was expected to account for approximately 55–60% of Non-Americas revenue over the initial years of the projection period. This concentration in a single product creates vulnerability to product-specific adverse events, including clinical safety signals, regulatory actions, or unexpected competitive entry, that would not be fully captured by a sector-wide beta.
• PBI's nascent operations: At the valuation date, PBI had been in existence for only approximately three-and-a-half months, employed only 52 individuals, and had no operating history or track record of independent commercialization. While PBI was expected to grow its capabilities over time (and indeed did grow to 185 employees by 2020), the valuation must be conducted based on the information available as of the valuation date. At that date, PBI's ability to execute the commercialization of PPC's IP portfolio across 68 country markets was untested.
2. Quantification. Based on the foregoing factors, we have determined that an asset-specific risk premium in the range of 1.0% to 3.0% is warranted for the PCT cash flows. For purposes of this analysis, we have adopted an asset-specific risk premium of 1.75%, which falls at the mid-point of the supportable range and reflects a balanced assessment of the following specific risk factors:
(a) Pipeline attrition risk for clinical-stage compounds. Several compounds included in the PCT IP were in Phase II or Phase III clinical development as of the valuation date. The probability of technical and regulatory success for these compounds ranged from approximately 25% to 55%, depending on the stage of development and therapeutic area. While risk-adjusted probability weightings were applied to the revenue projections in the companion DCF model, the inherent uncertainty surrounding clinical outcomes — including the possibility of complete compound failure — warrants an incremental risk premium beyond what is captured by probability-weighted expected values.
(b) Market-entry uncertainty in emerging markets. The Non-Americas Territory includes a significant number of emerging markets in Asia, the Middle East, Africa, and Eastern Europe. As of the valuation date, PBI had not yet established commercial operations in many of these markets, and the projected cash flows from emerging markets were subject to significant uncertainty regarding regulatory timelines, pricing and reimbursement outcomes, distribution infrastructure, and competitive dynamics. These uncertainties are not fully captured by the betas of the comparable companies, which are predominantly headquartered in developed markets and derive the majority of their revenue from established pharmaceutical markets.
(c) PBI's untested commercialization capability. As discussed above, PBI was a newly incorporated entity with only 52 employees and no track record of independent pharmaceutical commercialization. The projected cash flows assumed that PBI would successfully build out its commercial infrastructure across 68 country markets, recruit and retain qualified personnel, establish distribution networks, and navigate diverse regulatory environments — all activities that PBI had not yet demonstrated the capacity to execute at the valuation date. The risk that PBI would underperform relative to these assumptions warrants an incremental risk premium.
3. IRS's Failure to Account for Asset-Specific Risk
The IRS's 7.2% WACC appears to include no asset-specific risk premium, or at most an inadequate one. This omission is a fundamental methodological error for several reasons:
First, Treas. Reg. § 1.482-7(g)(4)(vi) expressly requires that the discount rate used in the income method for PCT valuations "reflect the riskiness of the relevant activities and the projected cash flows." The regulation does not direct the use of an enterprise-level WACC; it requires a rate tailored to the specific risk profile of the activities and cash flows being valued. The IRS's failure to adjust its discount rate for the specific risks of the Non-Americas IP stream is directly contrary to this regulatory mandate.
Second, the IRS apparently treated the intangible cash flows as having the same risk profile as PPC's overall enterprise, ignoring the incremental risk of the carved-out Non-Americas IP stream. This approach conflates the risk of PPC's established Americas business — which benefits from a mature commercial infrastructure, regulatory approvals already in hand, established distribution networks, and proven market demand — with the risk of a newly created Irish subsidiary exploiting IP in 68 foreign markets. These two income streams have materially different risk characteristics, and applying the same discount rate to both is analytically unsound.
Third, the academic and practitioner literature on IP valuation and transfer pricing consistently supports the use of asset-specific or investment-specific discount rates when the cash flow stream being valued has materially different risk characteristics from the entity's overall operations. The failure to incorporate an asset-specific risk premium is not merely a difference of judgment — it is a departure from accepted methodology.
F. Cost of Debt
1. PPC's Borrowing Cost
The after-tax cost of debt is the second component of the WACC (in addition to the cost of equity). PPC's pre-tax cost of debt as of the valuation date is determined by reference to PPC's outstanding debt instruments and borrowing terms.
As of July 1, 2012, PPC had access to a senior revolving credit facility administered by Hargrove National Bank, N.A. The facility provided total commitments of $1.5 billion and bore interest at a rate of LIBOR plus a margin of 125 basis points. As of the valuation date, the 3-month LIBOR rate was approximately 0.46%, resulting in an all-in borrowing rate of approximately 1.71%. PPC also had outstanding senior unsecured notes with a weighted average coupon rate of approximately 4.25%, issued in the 2009–2011 timeframe.
Taking a weighted average of PPC's revolving credit facility and outstanding notes, based on drawn amounts and outstanding principal as of the valuation date, PPC's blended pre-tax cost of debt was approximately 3.80%. Applying the 2012 U.S. federal statutory corporate tax rate of 35% (pre-TCJA), the after-tax cost of debt is:
After-tax cost of debt = 3.80% × (1 - 0.35) = 2.47%
2. IRS's Cost of Debt
Based on our review of Dr. Washburne's analysis, the IRS appears to have used a broadly similar pre-tax cost of debt, although the precise rate used by the IRS is not entirely clear from the available documentation. To the extent the IRS used a lower pre-tax cost of debt (for example, by relying primarily on the revolving credit facility rate rather than a blended rate incorporating the higher-coupon outstanding notes), this would further contribute to the understated WACC, though the impact of any cost-of-debt difference is relatively modest given the equity-heavy capital structure.
G. Capital Structure Weights
1. Market-Value Capital Structure
The WACC weights the cost of equity and the after-tax cost of debt by the proportions of equity and debt in the company's capital structure, measured at market value. Using market values rather than book values is the accepted approach in valuation practice because market values reflect the current opportunity cost of capital.
As of July 1, 2012, PPC's capital structure was as follows:
PPC's equity-heavy capital structure is typical of specialty pharmaceutical companies, which tend to rely more heavily on equity financing than on debt. This is driven by the high-risk nature of pharmaceutical R&D and the resulting preference of pharmaceutical companies for maintaining financial flexibility and low leverage.
2. Target vs. Actual Capital Structure
We considered whether it would be more appropriate to use a target capital structure (based on the median capital structure of the comparable companies) or PPC's actual capital structure as of the valuation date. The median debt-to-total-capital ratio for the twelve comparable companies was approximately 14.8%, and the mean was approximately 16.2%. PPC's actual debt-to-total-capital ratio of 15.9% is very close to the comparable company median and mean, indicating no meaningful difference between PPC's actual capital structure and the industry norm.
Accordingly, we have used PPC's actual market-value capital structure as of the valuation date: 84.1% equity and 15.9% debt.
The IRS appears to have used a broadly similar capital structure, and any difference in capital structure weights is not a significant driver of the WACC gap between the parties.
V. WACC Build-Up Summary
A. PPC / Whitmore WACC Derivation
The following table presents the complete WACC build-up as derived by Whitmore Valuation Group:
The unrounded WACC is approximately 9.82%, which we round to 9.8% for purposes of the DCF analysis. This rounding has a negligible impact on the resulting PCT valuation.
B. IRS WACC Derivation (Reconstructed)
Based on our review of Dr. Washburne's analysis and the information available from the IRS's examination workpapers, we have reconstructed the IRS's 7.2% WACC as follows:
We note that our reconstruction of the IRS's WACC is based on the best available information and may not precisely match Dr. Washburne's calculations in every detail. However, the reconstructed build-up produces a result consistent with the IRS's stated 7.2% WACC and allows for meaningful comparison with our 9.8% derivation.
C. Sources of Divergence — Component-by-Component Comparison
The following table presents a side-by-side comparison of each WACC component, identifying the divergence and its approximate contribution to the overall 2.6 percentage point gap between Whitmore's 9.8% WACC and the IRS's 7.2% WACC:
The primary drivers of the 2.6 percentage point WACC gap, in order of approximate contribution, are:
1. Risk-free rate maturity mismatch (~0.9 pp): The IRS's use of the 10-year Treasury yield (1.65%) rather than the 20-year yield (2.71%), which flows through both the CAPM directly and indirectly.
2. Equity risk premium (~0.6 pp): The IRS's selection of a below-median 5.50% ERP versus our 6.10%.
3. Beta understatement (~0.4 pp): The IRS's use of a 0.95 beta versus the 1.20 beta supported by the pharmaceutical comparable set.
4. Asset-specific risk premium (~0.4 pp): The IRS's nominal 0.50% asset-specific premium versus our 1.75%, reflecting the IRS's failure to adequately account for the specific risks of the Non-Americas IP stream.
5. Size premium omission (~0.3 pp): The IRS's apparent omission of any size premium adjustment.
While no single component fully explains the 2.6 percentage point gap, the cumulative effect of the IRS's systematic downward bias across virtually every component of the WACC produces a discount rate that is materially understated and inconsistent with the risk characteristics of the pharmaceutical IP being valued.
VI. Sensitivity Analysis — Impact of discount Rate on PCT Valuation
A. PCT Value at Various discount Rates
The income-method DCF valuation is highly sensitive to the discount rate, particularly when the cash flow projection period is long (as is the case with pharmaceutical intangible property, where the projection period extends approximately 17–22 years). Small changes in the discount rate produce large changes in the present value of projected cash flows.
The following table illustrates this sensitivity by presenting the PCT value at discount rates ranging from 6.0% to 12.0% in 0.5% increments, holding all other assumptions constant (i.e., using the base-case revenue projections from the companion PCT Valuation Analysis report):
Note: PCT values presented in the table above reflect the base-case revenue projection scenario. The arm's-length range of $278 million to $361 million reported in the Executive Summary reflects the application of the 9.8% WACC to the low-case, base-case, and high-case revenue projection scenarios, as detailed in the companion PCT Valuation Analysis report. At the 9.8% WACC, the base-case revenue scenario produces a PCT value of approximately $312 million (the midpoint of the arm's-length range), which equals the actual PCT payment.
The sensitivity analysis demonstrates several important points. First, the PCT valuation is extremely sensitive to the discount rate: each 100 basis point increase in the WACC reduces the PCT value by approximately $100–$150 million over the relevant range. Second, the 2.6 percentage point difference between the IRS's 7.2% and Whitmore's 9.8% translates into approximately $390 million in PCT value difference under the base-case scenario — nearly the entirety of the $540 million gap between the IRS's $852 million valuation and the actual $312 million payment. Third, the actual $312 million payment is fully consistent with a WACC in the range of 9.5%–11.5%, which encompasses the specialty pharmaceutical cost-of-capital range supported by the evidence in this memorandum.
B. Breakeven Analysis
The breakeven analysis identifies the discount rates at which the income-method PCT value equals specific reference points:
• Breakeven at $312 million (actual PCT payment, base-case revenue scenario): The discount rate at which the base-case PCT value equals $312 million is approximately 9.8% — precisely the WACC derived by Whitmore. This result confirms the internal consistency of Whitmore's analysis: the derived WACC produces a PCT value equal to the actual payment under the base-case revenue projections.
• Breakeven at $361 million (top of arm's-length range): The discount rate at which the base-case PCT value equals $361 million is approximately 11.1%. This demonstrates that even at the top of the arm's-length range, the implied WACC (11.1%) is well within the range of specialty pharmaceutical cost-of-capital estimates and far above the IRS's 7.2%.
• Breakeven at $278 million (bottom of arm's-length range): The discount rate at which the base-case PCT value equals $278 million is approximately 12.2%. Even this rate is not unreasonable for a high-risk pharmaceutical IP portfolio with significant clinical-stage and emerging-market exposure.
The breakeven analysis demonstrates that even modest upward adjustments from the IRS's 7.2% rate materially reduce the PCT value toward PPC's position. For example, increasing the IRS's WACC by just 1.0 percentage point — from 7.2% to 8.2% — would reduce the PCT value from $852 million to approximately $672 million, eliminating nearly one-third of the purported $540 million gap. An increase of 2.0 percentage points — to 9.2% — would reduce the PCT value to approximately $530 million, eliminating nearly 60% of the gap.
C. Revenue Projection Sensitivity
The discount rate interacts with revenue projection assumptions in determining the PCT value. A higher discount rate applied to higher revenue projections may produce a similar present value as a lower discount rate applied to lower revenue projections. This interaction means that the discount rate dispute cannot be evaluated in isolation from the revenue projection dispute.
As detailed in the companion PCT Valuation Analysis report, the IRS not only used a lower discount rate (7.2% vs. 9.8%) but also used higher revenue projections for the Non-Americas markets. The IRS's revenue projections assumed more aggressive market penetration rates, earlier market-entry timelines in certain emerging markets, and more favorable pricing assumptions than those supported by the contemporaneous evidence available as of the valuation date. The combined effect of the lower discount rate and higher revenue projections produced the IRS's $852 million PCT value — an amount that is doubly inflated relative to the arm's-length result.
The full revenue projection analysis, including the interaction between discount rate and revenue projection scenarios, is presented in Appendix C to this memorandum (sensitivity tables cross-tabulating WACC rates with low/base/high revenue projection scenarios) and in the companion PCT Valuation Analysis report. In summary, under all three revenue projection scenarios (low, base, high), the 9.8% WACC produces PCT values within or near the arm's-length range, while the 7.2% WACC produces PCT values that substantially exceed the arm's-length range under every revenue projection scenario.
VII. Critique of the IRS's 7.2% discount Rate
A. Failure to Account for Pharmaceutical-Industry Risk